SWOG clinical trial number
SWOG-9009
Pilot Study for Analysis of Lymphocyte Subsets and Natural Killer Activity after Treatment with Levamisole
Closed
Phase
Accrual
95%
Published
Abbreviated Title
Pilot Study for Analysis of Lymphocyte Subsets and Natural Killer Activity after Treatment with Levamisole
Activated
12/15/1990
Closed
08/07/1992
Research committees
Gastrointestinal Cancer
Publication Information Expand/Collapse
1999
Association of immune parameters with clinical outcome in stage III colon cancer: Results of Southwest Oncology Group Protocol 9009.
1997
Immunologic reconstitution following adjuvant 5FU and levamisole (LMS) correlates with disease free survival in stage III colon cancer: Report of Southwest Oncology Group (SWOG) protocol #9009.
Other Clinical Trials
SWOG Clinical Trial Number
S2303
Randomized Phase II/III Trial of 2nd Line Nivolumab + Paclitaxel + Ramucirumab versus Paclitaxel + Ramucirumab in Patients with PD-L1 CPS ≥ 1 Advanced Gastric and Esophageal Adenocarcinoma (PARAMUNE)
Research Committee(s)
Gastrointestinal Cancer
Activated
05/06/2024
Open
SWOG Clinical Trial Number
CTSU/A022101
A Pragmatic Randomized Phase III Trial Evaluating Total Ablative Therapy for Patients with Limited Metastatic Colorectal Cancer: Evaluating Radiation, Ablation, and Surgery (ERASur)
Research Committee(s)
Gastrointestinal Cancer
Activated
01/10/2023
Open
SWOG Clinical Trial Number
S2107
Randomized Phase II Trial of Encorafenib and Cetuximab with or Without Nivolumab (NSC #748726) for Patients with Previously Treated, Microsatellite Stable, BRAFV600E Metastatic and/or Unresectable Colorectal Cancer
Research Committee(s)
Gastrointestinal Cancer
Activated
06/06/2022
Accrual
83%
Open
Phase